Perceptions of ductal carcinoma in situ (DCIS) among UK health professionals by Kennedy, F et al.
This is a repository copy of Perceptions of ductal carcinoma in situ (DCIS) among UK 
health professionals.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/95491/
Version: Accepted Version
Article:
Kennedy, F orcid.org/0000-0002-4910-2505, Harcourt, D and Rumsey, N (2009) 
Perceptions of ductal carcinoma in situ (DCIS) among UK health professionals. The 
Breast, 18 (2). pp. 89-93. ISSN 1532-3080 
https://doi.org/10.1016/j.breast.2009.01.004
© 2009, Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 
4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
  
 
Perceptions of Ductal Carcinoma in Situ (DCIS) 
among UK health professionals 
 
Fiona Kennedya*, Diana Harcourta, Nichola Rumseya 
 
a
 Centre for Appearance Research, Faculty of Health & Life Sciences, 
University of the West of England, Bristol, BS16 1QY, United Kingdom 
 
* Corresponding author: Centre for Appearance Research, Faculty of Health & Life 
Sciences, University of the West of England, Bristol, BS16 1QY, United Kingdom.  
Tel: 0117 3281890.  Fax: 0117 3283645.  Email: Fiona2.Kennedy@uwe.ac.uk 
 
 
 
 
 
 
 
 
 2
Abstract 
 
Ductal carcinoma in situ (DCIS) is a complex medical entity which presents challenges 
for the health professionals who manage the treatment and support of the increasing 
numbers of women diagnosed with the condition.  Health professionals’ perceptions and 
experiences of working with DCIS have rarely been explored, which this study sought 
to address.  Two hundred and ninety-six UK health professionals involved with the 
treatment of DCIS patients were surveyed.  Respondents had diverse perceptions of the 
condition.  Explaining DCIS to patients was challenging for many respondents, and the 
terminology used varied considerably.  This exploratory study highlights the substantial 
diversity in the perceptions and communication of DCIS among UK health 
professionals.  The nature and implication of these variations and the professional 
challenges presented by DCIS warrant further exploration and debate in order to inform 
the provision of appropriate care, support and information to patients.   
 
Keywords: Ductal carcinoma in situ (DCIS); health professionals; perception; 
communication. 
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Introduction 
 
Diagnoses of ductal carcinoma in situ (DCIS) have risen dramatically since the National 
Health Service Breast Screening Programme (NHSBSP) was established and it now 
represents 20% of screen-detected breast cancers in the UK.1  DCIS is a non-invasive 
condition, where cancer cells are confined to the ducts of the breast.2  Whilst these cells 
are contained the condition is not life-threatening, and following treatment most patients 
have an excellent prognosis.3  However, despite this positive outlook, when compared 
to invasive breast cancer (IBC) patients ‘different’ psychosocial problems may occur,4 
which may be due to the asymptomatic nature of the condition,5 patients’ lack of prior 
awareness of DCIS,6-7 the uncertainty of the natural history of the condition,8 and the 
treatment paradox it presents (e.g. extensive treatment, including mastectomy, to treat 
non-invasive/early disease).9 
 
Recent research suggests that DCIS is a challenging and confusing diagnosis for 
patients, because of the complexity of the condition,6, 10-13 and that treatment 
recommendations and the terminology used to communicate DCIS may contribute to 
their uncertainty.14  Furthermore, women diagnosed with DCIS have expressed diverse 
perceptions of the nature of the condition ranging from breast cancer to pre-cancer, 
which may impact on their feelings and experiences of treatment, support and 
adjustment.10  This diversity amongst patients may be due in part to the varied opinions 
about the condition, styles of communication and preferred terminology among health 
professionals, which has been reported anecdotally and in recent research.10, 15-16  
Furthermore, debate about the most appropriate treatment for DCIS is ongoing;17 among 
radiation oncologists management of DCIS varied according to geographical region 
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(North America versus Europe) and academic status, 18 and a recent study with 
clinicians highlighted the difficulty of DCIS treatment decision-making.19   
 
The inherent complexity of DCIS and the increasing evidence collated among patients, 
suggest that professionals’ own attitudes and perceptions about the condition are 
important.  To date, only one study has explored this area.  Partridge et al. (2008) found 
considerable differences in professionals’ perceptions, communication and management 
of DCIS;19 however, this study was conducted in the United States and may not 
necessarily translate to UK practices.  Furthermore, the authors did not specifically 
explore similarities and differences across different professional groups, with the focus 
generally limited to surgeons and medical oncologists.  They did not include 
professionals who in the UK play a vital role in communicating with patients, such as 
specialist breast care nurses (BCNs).20-21  Therefore, the current exploratory study 
aimed to investigate the terminology, perception and experiences of DCIS among UK 
health professionals, and to compare responses across a variety of professional groups. 
 
 
Materials and methods 
 
Design and materials 
A brief survey was developed, piloted and made available for completion online, via 
email or post.  In addition to demographic (age, gender, profession, personal experience 
of DCIS) and practice details (years in profession/breast speciality, number of new 
cases of ‘pure DCIS’ seen per year), the survey explored 2 main areas: 1) Terminology 
in DCIS was explored with two separate open-ended questions that asked participants to 
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explain how they described low and high grade DCIS to patients, and 2) Attitudes 
towards DCIS, which incorporated the following four concepts: a) perception of DCIS, 
which was explored using a single item based on three verbatim quotes (“breast cancer”, 
“fall between normal and cancer” or “not cancer, pre-cancer”) derived from a recent 
study involving DCIS patients;10 b) general risk for patients’ long-term health 
(measured using a 5-point scale: low to high risk); c) explaining, including the 
perceived difficulty of describing DCIS generally (5-point scale: not difficult at all to 
very difficult), and in comparison to the difficulty of explaining invasive breast cancer 
(IBC) (less, same as or more difficult); and d) challenges of DCIS which asked 
participants to state the three greatest challenges facing patients and health professional 
themselves (ranked according to difficulty, e.g. 1 = most challenging).     
 
Recruitment and participants  
Ethical approval was sought from the Faculty of Health and Life Sciences Ethics 
Committee at the University of the West of England, Bristol.  Additionally, as the target 
population was NHS staff, advice was sought from the Central Office for Research 
Ethics Committee (COREC).  COREC confirmed that NHS ethical approval was not 
required because the proposed recruitment strategies via professional bodies and 
conferences did not involve recruiting directly through the NHS.  
 
UK health professionals involved with DCIS were informed and directed to the survey 
via various professional bodies, organisations and conferences aimed at a variety of 
professions including specialist BCNs, surgeons, physicians, radiologists, 
radiographers, oncologists and pathologists.  All participants gave informed consent and 
were notified that their responses were strictly confidential and could be entirely 
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anonymous.  Contact details were only required if participants wished to enter a prize 
draw, receive feedback on the results or participate in further research.  
 
Statistical analysis 
All quantitative data were analysed using the Statistical Package for the Social Sciences 
(SPSS) version 13.  Descriptive statistics explored frequency responses and chi-square 
analysis was undertaken to compare the professional groups.  Some questions were 
specifically aimed towards professionals who have direct patient contact (e.g. BCNs and 
surgeons who explain DCIS to patients and must choose their terminology), as opposed 
to those with little face-to-face patient contact (e.g. pathologists).  On review of the 
responses to these questions it was clear that those with little patient contact did not find 
these questions relevant and their responses were subsequently excluded from the 
analysis of these items.  Binary logistic regression explored the factors associated with 
health professionals’ views of the long-term risk of DCIS.  Qualitative data provided in 
response to the open-ended questions were analysed using content analysis.   
 
 
Results 
 
Two hundred and ninety-six health professionals participated, the majority of whom 
were surgeons (n = 90), breast care nurses (n = 51), pathologists (n = 47) or radiologists 
(n = 40).  Demographic details by professional group are presented in Table 1.  The 
mean age of all participants was 47.2 years, 56.1% were female and 12.2% indicated 
having a personal experience of DCIS (e.g. self, family).  The number of new cases of 
‘pure DCIS’ seen each year was most frequently in the range of 11-20 (35.1%).   
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Table 1 about here  
 
Terminology 
 
Two questions explored how professionals described DCIS to patients according to 
whether it was low or high grade.  Excluding pathologists, almost one-third described 
low grade DCIS as a type of ‘cancer’, and an additional 20% described it as 
‘cancerous’, ‘malignant’ ‘cells’ or ‘changes’ (see Table 2).  In contrast, 21.8% 
explained it as a ‘pre-cancer(ous) condition’ or ‘pre-cancer(ous) cells’ and 17.2% as an 
‘abnormality’, ‘abnormal cells’ or ‘cell changes’, in which there was no mention of 
cancer or malignancy.  When these four main terms were dichotomised into two 
response groups (cancer or not cancer – see Table 2 for details), oncologists were 
significantly less likely to use the terms that mentioned cancer or malignancy: χ2 = 
14.98, df = 5, p = 0.01.  
 
Many professionals described the additional information they offered to patients, such 
as the ‘risk of progression’ (n = 112), the ‘contained’ (n = 106) and ‘early’ (n = 55) 
nature of the condition.  The main differences in responses to the high grade scenario 
were: higher risk of progression (n = 131), the necessity/increased urgency of treatment 
(n = 50), less positive language (n = 42), uncertainty of the diagnosis/possibility of 
invasive disease (n = 27), and the faster timescale for progression (n = 23). 
 
Table 2 about here 
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Attitudes towards DCIS 
 
a) Perceptions of DCIS 
Professionals held diverse perceptions of DCIS; 35.1% perceived it as ‘breast cancer’, 
whilst the remainder considered it to be ‘not cancer, pre-cancer’ (43.9%) or a ‘stage 
between normal and cancer’ (16.9%).  Twelve professionals did not respond to this item 
(4.1%).  When dichotomised into two response groups (breast cancer; not breast cancer, 
i.e. ‘fall between’ and ‘pre-cancer’), oncologists were also significantly less likely than 
other professions to view DCIS as breast cancer: χ2 = 14.60, df = 6, p = 0.024 (Figure 
1).   
 
Figure 1 about here 
 
b) Perceived risk of DCIS 
The perceived risk of pure DCIS for patients’ long-term health was rated as low 
(43.3%), medium (41.6%) or high (15%) and responses significantly differed by 
profession: χ² = 32.4, df = 6, p < 0.001.  Mann-Whitney U with Holms-Stepdown 
procedure22 to adjust for inflated type I error rate confirmed that BCNs perceived a 
lower risk than pathologists, and that surgeons and oncologists perceived a lower risk 
than radiologists, radiographers and pathologists.  Similar to the analysis of Partridge et 
al, 19 logistic regression identified factors associated with perceiving a higher risk of 
DCIS (dichotomised into low-medium vs. high).  The factors entered were age, gender, 
number of years in profession, personal experience, number of new DCIS patients seen 
per year (deviation coding, comparing to mean), perception (breast cancer or not), and 
difficulty explaining DCIS compared to IBC.  Unfortunately, professional group could 
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not be entered as a predictor because none of the oncologists viewed DCIS as a high 
risk, and this empty cell biased the regression coefficients and resulted in non-
convergence.  Therefore, excluding profession, the model found that those who saw in 
excess of 40 new DCIS patients per year were over 3 times more likely to view DCIS as 
a higher risk (odds ratio 3.05, CI 1.38 – 6.73, p = 0.006).  Reporting more difficulty 
explaining DCIS compared to IBC, a ‘breast cancer’ perception and older age of health 
professional were also significant predictors of a higher perceived risk for patients’ 
long-term health (see Table 3).   
 
Table 3 about here 
 
c) Explaining DCIS to patients 
Of the 246 responses (excluding pathologists who did not have direct patient contact), 
54 professionals (22%) found it somewhat or very difficult to explain DCIS to patients, 
whereas 46.7% indicated it was not difficult, and the remaining 31.3% were undecided 
(neither option).  However, in contrast and surprisingly given the previous agreement of 
low-medium perceived risk, 51.4% found DCIS more difficult to explain to patients 
than IBC (only 9% found DCIS easier to explain).  Responses to open-ended questions 
revealed that the uncertainty of progression, treatment paradox, and discrepancies in 
terminology and professional opinion were perceived as reasons for this difficulty.   
 
Chi-square analysis revealed a significant difference between the professional groups in 
the difficulty explaining DCIS compared to IBC (dichotomised as more difficult vs. 
same or easier): χ² = 15.2, df = 5, p = 0.009.  Further partitioned chi-square analysis 
revealed that: 1) surgeons and oncologists reported more difficulty than physicians, and 
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2) surgeons, oncologists, BCNs and radiologists reported more difficulty than 
radiographers.  The percentages within each category can be viewed in Table 4. 
 
Table 4 about here 
 
d) Challenges of DCIS 
The challenge of DCIS for patients that was most frequently reported by professionals 
was ‘understanding the condition’; cited 134 times across all responses, and this was 
also viewed as the most challenging by 103 participants (e.g. ranked as the number 1 
challenge).  Ninety-seven responses emphasised the ‘treatment paradox’ (ranked as the 
number 1 by 46), particularly in relation to recommending a mastectomy to treat a non-
invasive/early disease.  The ‘long-term risk’ (n = 97), ‘treatment decisions’ (n = 81) and 
‘distress/psychosocial issues’ (n = 63) were also viewed as challenges for patients.   
 
Whilst there were similarities between professional groups in their perceptions of the 
challenges faced by patients, there was less concordance in participants’ reports of the 
DCIS-related challenges they themselves faced, possibly due to the variety of 
interactions that different professions have with the condition (e.g. explaining it to 
patients, diagnosing the condition).  For example, pathologists identified technical 
difficulties associated with assessing excision specimens, whilst the remaining 
professions described their most frequent challenge as ‘explaining’ DCIS to patients 
(cited 95 times across all responses and ranked as number 1 by 68).  This further 
demonstrates the difficulty of communicating DCIS to patients.  Seventy-six responses 
emphasised ‘professional issues’, which incorporated fear of overdiagnosis, uncertainty, 
and the lack of research/evidence base of the natural history of DCIS.  ‘Communication 
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of treatment’ (cited by 70), ‘treatment decisions’ (cited by 69) and ‘disease/diagnosis-
related issues’ (cited by 64) such as estimating the extent (especially among radiologists 
and radiographers), were also frequently reported challenges.   
 
 
Discussion  
 
The findings from this exploratory study highlight the substantial variation in the 
perceptions and communication of DCIS among UK health professionals, and support 
recent findings in the United States.19  The current study also validates the diverse 
terminology and difficulty of communicating DCIS emphasised in a recent study 
involving patients,10 which confirms that these may influence patients’ perceptions and 
experiences.  In addition, the findings highlight that DCIS can be a challenging 
diagnosis for professionals to manage, especially in relation to the uncertainty 
surrounding the condition and communicating with patients.   
 
There was considerable diversity in perceptions of DCIS both within and between 
professional groups.  However, in each group a small majority viewed it as not being 
breast cancer (identifying instead with the ‘pre-cancer’ or ‘fall between’ options), and it 
was noticeable that oncologists were less likely to perceive DCIS as breast cancer than 
other professionals.  This may be because the majority of patients are treated by surgery 
alone. Consequently, the oncologists in this study saw fewer new cases of ‘pure DCIS’ 
each year than other professional groups (see Table 1).  However, it should be noted 
that there were fewer oncologists in this study than the numbers of respondents from 
 12
other professional groups (e.g. surgeons, specialist BCNs).  Further research is required 
to explore the experiences of different professionals groups in more detail.   
 
In general, DCIS was viewed as a low or medium risk to patients’ long-term health, 
reflecting prevailing medical knowledge concerning the condition.  However, it was 
interesting to find that oncologists and surgeons perceived DCIS to be a lower risk than 
did pathologists, radiologists and radiographers, and that BCNs viewed it as less risky 
than pathologists did.  In addition, those who saw a larger number of new DCIS cases 
each year (which may also be influenced by their profession) perceived it as having a 
greater long-term health risk for patients.  Perceptions of higher risk were also 
associated with more difficulty explaining DCIS than IBC and with perceiving DCIS as 
‘breast cancer’.  These associations do not infer causality and cannot necessarily be 
generalised, but they do suggest that the diversity of professionals’ own views about 
DCIS influence how they perceive concepts such as risk, which in turn are likely to 
impact on their management of the condition and communication with patients.   
 
The terms health professionals used to describe DCIS to patients varied considerably.19  
Over 40% of professionals described the condition as abnormal cells, an abnormality or 
a pre-cancer(ous) condition or cells, all of which could be seen as minimising the 
impact of the diagnosis.  In contrast, 53.1% reported using terms that emphasised a type 
of cancer (albeit non-invasive, early or pre-invasive) or cancerous cells or changes, 
which could be interpreted as overstating the risks of the condition.  The precursory 
terms ‘early’ or ‘non-invasive’ might act to lessen the seriousness of the diagnosis if 
they are understood and acknowledged by patients.  However, anecdotal evidence 
suggests that many patients focus on the term ‘carcinoma’ or ‘cancer’ when they are 
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diagnosed with DCIS,14-15 both of which are associated with metastatic disease and 
mortality.15  The general inconsistency in language and terms used in DCIS has been 
reported to leave patients confused.6, 10  From a patient-centred perspective it is 
imperative that the language health professionals use to explain DCIS is understandable, 
coherent and consistent,23, 6 so that patients can clearly comprehend the condition and 
the rationale for the recommended treatment. 
 
Furthermore, explaining DCIS was reported to be a particular challenge for many 
professionals, with a substantial number reporting that this was the most difficult aspect 
of the condition for them.  Over half found DCIS more complex to explain to patients 
than IBC.  This finding is intriguing and warrants further research.  The difficulty may 
stem from the inherent uncertainty and paradoxical nature of the condition.  This study 
indicates that efforts to enhance professionals’ ability to confidently and consistently 
explain the condition to patients would offer benefits both for them and for patients 
affected by DCIS.  Communication advice and training in this area is currently under 
development in Australia.13   
 
It is important to acknowledge the limitations of the method undertaken in this study.  
In particular, respondents were predominantly from four professions: surgeons, breast 
care nurses, radiologists and pathologists, and therefore some professional groups had 
less representation in the sample.  Furthermore, the method of distributing the survey 
precluded the calculation of a total population size or response rate.  The survey was 
presented as an exploration of health professionals’ views rather than specifically about 
the challenges of DCIS, although it is possible that it attracted those professionals who 
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were particularly interested in the challenges of DCIS.  Therefore, the findings should 
be viewed in light of these caveats. 
 
 
Conclusion 
 
It is evident that DCIS can be a complex and challenging diagnosis for health 
professionals to deliver to patients.  The challenges inherent in explaining the condition 
reflect the uncertainty, complexity, ongoing debates about the condition and a lack of 
clarity about optimum treatment.  Research findings from the UK Sloane Project,24 a 
national audit of screen-detected DCIS, will hopefully ameliorate some of the 
difficulties and challenges for professionals in clinical practice.  In the meantime, it 
would be beneficial for professionals to consider the impact of their own views, and the 
diversity of views within the health care professions, on patients’ experiences of being 
diagnosed and treated for DCIS. 
 
In view of this diversity of views it would be useful to debate the appropriate 
terminology and the most suitable information to offer women diagnosed with DCIS.  It 
would seem logical to suggest that information should be consistent across different 
information sources (e.g. verbal, leaflets, internet).  However, given the variety of views 
and terminology currently used, and the extensive research literature which emphasises 
the benefits of individualised communication and information provision,25 future 
research should address whether greater consistency in the messages given to patients 
about a complex condition such as DCIS is possible or even desirable. 
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Table 1 – Demographic characteristics of the sample (n = 296) 
 Specialist BCN 
n=50 
Physician 
n=16 
Surgeon 
n=90 
Radiographer 
n=25 
Radiologist 
n=40 
Oncologist 
n=27 
Pathologist 
n=47 
Overall 
n=296 
Age (years) 46.0 48.1 47.4 52.0 49.7 42.3 46.1 47.2 
Gender - male/female 0/50 7/9 60/29 0/25 20/20 16/11 26/21 129/166 
Years in: 
- profession (general) 
- breast speciality 
 
16.7 
9.4 
 
14.9 
11.2 
 
15.4 
10.3 
 
24.0 
12.7 
 
20.4 
14.9 
 
13.7 
10.1 
 
20.2 
14.3 
 
17.6 
12.2 
Personal experience % 11.8% 18.8% 6.7% 28% 10% 7.4% 17% 12.2% 
No. of new cases of ‘pure DCIS’: # 
- less than 10 
- 11-20 
- 21-30 
- 31-40 
- 41+ 
 
12% 
24% 
32% 
8% 
24% 
 
6.3% 
43.8% 
18.8% 
18.8% 
12.5% 
 
11.1% 
47.8% 
23.3% 
8.9% 
8.9% 
 
21.7% 
21.7% 
21.7% 
13% 
21.7% 
 
10.3% 
17.9% 
20.5% 
20.5% 
30.8% 
 
40.7% 
25.9% 
22.2% 
7.4% 
3.7% 
 
15.2% 
45.7% 
8.7% 
4.3% 
26.1% 
 
15.1% 
35.1% 
21.6% 
10.3% 
17.9% 
# per year 
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Table 2 – Terms used by participants to describe DCIS to patients 
Term used Number (%) of responses 
Cancer$ 
- form of cancer/breast cancer 
- non-invasive/in situ cancer 
- pre-malignant/pre-invasive cancer 
- cancerous or malignant cells/change 
127 (53.1%)  
- 45 (18.8%) 
- 21 (8.8%) 
- 12 (5%) 
- 49 (20.5%) 
Not cancer$ 
Abnormality/abnormal cells/cell changes 
Pre-cancer(ous) cells or condition  
93 (38.9%)  
41 (17.2%) 
52 (21.8%)  
DCIS/ductal carcinoma in situ # 7 (2.4%) 
Other* 12 (5%) 
* Other terms included: a warning sign/first step, risk/lesion, not a true cancer, unstable/unhealthy tissue 
# It is uncertain from the data whether those who use ‘DCIS’ further described the components of the diagnosis to their patients
  
$ The top 2 rows were used in the chi-square analysis on the main terms utilised (‘DCIS’ and ‘Other’ were excluded due to small 
numbers and lack of clarity whether the emphasis was on cancer or not)  
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Figure 1 – Perception of DCIS according to professional group (n = 284) 
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Table 3 – Factors associated with higher perceived risk of DCIS 
Higher perceived risk of DCIS B (SE) p Exp b 
(OR) 
95% CI for 
Exp b 
Constant -6.79 (2.12) 0.001 0.001  
     
41+ cases of DCIS (per year) 1.11 (0.40) 0.006 3.05 1.38-6.73 
More difficulty explaining (IBC) 0.99 (0.46) 0.029 2.71 1.11-6.66 
Breast cancer perception -0.81 (0.42) 0.052 0.44 0.20-1.01 
Older age 0.07 (0.04) 0.054 1.08 1.00-1.16 
Non-significant factors were gender, years in profession, personal experience. 
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Table 4 – Difficulty explaining DCIS compared to IBC, according to profession 
 % Same or less difficult % More difficult 
BCN (n = 51) 47.1 52.9 
Physician (n = 16) 75 25 
Surgeon (n = 90) 41.1 58.9 
Radiographer (n = 22) 77.3 22.7 
Radiologist (n = 39) 48.7 51.3 
Oncologist (n = 27) 37 63 
 
 
